Recode TX

Powering the future of genetic medicines through superior delivery

Menlo Park, United States · Founded 2020 · $189.0M raised

Employees
51–200
Founded
2020
Business Model
B2B
Total Funding
$189.0M
Last Round
$29.0M Venture RoundSep 2025
Rounds
3

About

ReCode Therapeutics is a genetic medicines company developing disease-modifying mRNA and gene correction therapeutics for genetically defined diseases with few or no current treatment options. The company's proprietary SORT (Selective ORgan Targeting) LNP platform, developed by co-founder Dr. Daniel Siegwart, enables delivery of genetic medicines to specific organs beyond the liver. Lead programs address cystic fibrosis (RCT2100, an inhaled mRNA therapy in Phase 2) and primary ciliary dyskinesia (PCD). The company is headquartered in Menlo Park, California and emerged from predecessor TranscripTx, which was founded in 2014; the ReCode Therapeutics name was adopted in 2020.

Summary

Recode TX is a Biotech company based in Menlo Park, United States, founded in 2020. It has raised $189.0M in total across 3 rounds, most recently a $29.0M Venture Round round in Sep 2025. Investors include Pfizer Ventures, EcoR1 Capital and OrbiMed.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Venture RoundVenture RoundSep 2025
$29.0M

Sign up to see all 3 rounds

Series A through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Recode TX on Indexed.vc
<a href="https://indexed.vc/companies/recode-tx"><img src="https://indexed.vc/api/badge/company/recode-tx" alt="Recode TX on Indexed.vc" width="260" height="76" /></a>